Galectin Therapeutics (GALT) Interest Coverage Ratio (2011 - 2026)
Galectin Therapeutics' (GALT) quarterly Interest Coverage Ratio came in at 2.05 in Q1 2026, up 54.71% year-on-year from 1.33 in Q1 2025, and down 18.17% quarter-over-quarter from 1.74 in Q4 2025.
Galectin Therapeutics (GALT) Interest Coverage Ratio (2011 - 2026) Analysis & Trends
Galectin Therapeutics' Interest Coverage Ratio history runs 16 years deep, the most recent figure standing at 2.05 for Q1 2026.
- On a quarterly basis, Interest Coverage Ratio rose 54.71% year-over-year to 2.05 in Q1 2026; TTM through Mar 2026 was 2.15, a 96.35% increase from a year earlier, with the FY2025 full-year figure at 0.21, up 55.3% from the prior year.
- Interest Coverage Ratio fell to 2.05 in Q1 2026 per GALT's latest filing, from 1.74 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 3.26 in Q4 2024 and bottomed at 43.77 in Q1 2022.
- The 5-year median for Interest Coverage Ratio is 8.9 (2024), against an average of 12.42.
- Across the five-year window, Interest Coverage Ratio surged 189.88% in 2024 and sank 153.27% in 2025, its largest moves.
- Year by year, Interest Coverage Ratio stood at 12.04 in 2022, then soared by 69.9% to 3.62 in 2023, then soared by 189.88% to 3.26 in 2024, then sank by 153.27% to 1.74 in 2025, then declined by 18.17% to 2.05 in 2026.
- Per Business Quant, the three latest GALT Interest Coverage Ratio figures stand at 2.05 (Q1 2026), 1.74 (Q4 2025), and 2.31 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Galectin Therapeutics | 227.21 Mn | 227.21 Mn | - | -2.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.05 |
| Dec 31, 2025 | -1.74 |
| Sep 30, 2025 | -2.31 |
| Jun 30, 2025 | -2.53 |
| Mar 31, 2025 | -4.53 |
| Dec 31, 2024 | 3.26 |
| Sep 30, 2024 | -6.07 |
| Jun 30, 2024 | -8.90 |
| Mar 31, 2024 | -9.17 |
| Dec 31, 2023 | -3.62 |
| Sep 30, 2023 | -10.98 |
| Jun 30, 2023 | -13.85 |
| Mar 31, 2023 | -22.48 |
| Dec 31, 2022 | -12.04 |
| Sep 30, 2022 | -30.19 |
| Jun 30, 2022 | -40.09 |
| Mar 31, 2022 | -43.77 |
| Dec 31, 2021 | 46.70 |
| Sep 30, 2021 | -74.27 |
| Jun 30, 2021 | -96.39 |